A Clinical Study of 6MW3211 in Patients With Renal Cancer

Inclusion Criteria: * Voluntarily participate in the study and sign the informed consent. * Advanced clear cell renal cancer. * At least one measurable tumor target lesion. * Life expectancy≥3 months. * Suitable organ functions. * Patients who had failed at least one line therapy. * ECOG 0-1. * The samples of tumor tissue should be provided Exclusion Criteria: * Patients who had received anti-tumor therapy/radiotherapy/immunotherapy within 4 weeks. * History of other malignant tumors within 5 years. * Patients with CNS metastasis. * History of active autoimmune diseases. * Patients with poor-controlled systemic diseases after treatment. * Patients with severe infection or requiring antibiotic treatment within 4 weeks before dosing. * Adverse reactions related to previous treatments failed to recover to CTCAE 5.0 ≤1 * Patients who had experienced immune-related adverse events (irAE) with grade 3 or above. * Patients who were allergic to any composition of experimental drug. * Subjects with poor treatment compliance. * Pregnant or lactating woman. * Live vaccination within 28 days before first dosing. * History of drug abuse or addiction * Patients with active HBV or HCV, or HIV antibody positive,or Tp-Ab positive.